Table 2:
Univariable model for progression-free and overall survival among patients with resectable disease
| PFS2 | PFS3 | PFS4 | OS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristica | n | HR (95% CI) | p | n | HR (95% CI) | p | n | HR (95% CI) | p | n | HR (95% CI) | p |
| Age | ||||||||||||
| <60 years | 97 | Ref | 62 | Ref | 45 | Ref | 97 | Ref | ||||
| ≥60 years | 37 | 1.34 (0.90 – 2.01) | 0.15 | 30 | 0.90 (0.56 – 1.44) | 0.66 | 25 | 0.72 (0.42 – 1.23) | 0.23 | 37 | 1.94 (1.11 – 3.39) | 0.02 |
| CRS | ||||||||||||
| No | 7 | Ref | 28 | Ref | 23 | Ref | 7 | Ref | ||||
| Yes | 127 | 0.37 (0.17 – 0.81) | 0.01 | 64 | 0.43 (0.26 – 0.70) | 0.001 | 47 | 0.74 (0.44 – 1.26) | 0.27 | 127 | 0.29 (0.12 – 0.68) | 0.004 |
| Residual disease | ||||||||||||
| R0 | 51 | Ref | 28 | Ref | 18 | Ref | 51 | Ref | ||||
| R≤1 cm | 19 | 2.57 (1.36 – 4.85 | 0.003 | 9 | 0.97 (0.43 – 2.19) | 0.94 | 7 | 1.10 (0.42 – 2.90) | 0.84 | 19 | 2.40 (0.78 – 7.38) | 0.13 |
| R>1 cm | 5 | 2.43 (0.72 – 5.85) | 0.18 | 2 | 0.93 (0.44 – 1.98) | 0.86 | 2 | 41.05 (3.57 – 472) | 0.003 | 5 | 4 (0.82 – 19.46) | 0.09 |
| Unknown | 52 | NA | NA | 25 | NA | NA | 20 | NA | NA | 52 | NA | NA |
| Chemotherapy | ||||||||||||
| No | 53 | Ref | 52 | Ref | 53 | Ref | 53 | Ref | ||||
| Yes | 81 | 1.18 (0.80 – 1.75) | 0.39 | 40 | 0.88 (0.57 – 1.36) | 0.56 | 17 | 0.99 (0.55 – 1.78) | 0.98 | 81 | 1.62 (0.94 – 2.81) | 0.08 |
| Targeted therapy | ||||||||||||
| No | 131 | Ref | 111 | Ref | 60 | Ref | 131 | Ref | ||||
| Yes | 3 | 2.22 (0.69 – 7.11) | 0.18 | 5 | 1.55 (0.62 – 3.89) | 0.35 | 10 | 1.41 (0.69 – 2.89) | 0.35 | 3 | 17.94 (3.58 – 89.9) | <0.001 |
| Radiotherapy | ||||||||||||
| No | 124 | Ref | 115 | Ref | 66 | Ref | 124 | Ref | ||||
| Yes | 10 | 0.69 (0.33 – 1.41) | 0.31 | 4 | 1.51 (0.55 – 4.17) | 0.42 | 4 | 1.23 (0.38 – 3.94) | 0.73 | 10 | 0.76 (0.30 – 1.92) | 0.57 |
| Hormonal therapy | ||||||||||||
| No | 100 | Ref | 55 | Ref | 31 | Ref | 100 | Ref | ||||
| Yes | 34 | 0.80 (0.51 – 1.26) | 0.34 | 37 | 0.92 (0.59 – 1.44) | 0.72 | 39 | 0.51 (0.30 – 0.86) | 0.01 | 34 | 0.87 (0.42 – 1.77) | 0.70 |
CRS = cytoreductive surgery. HR = Hazard ratio. NA = not applicable. OS = overall survival. PFS2 = progression-free survival after first recurrence. PFS3 = progression-free survival after second recurrence/progression. PFS4 = progression-free survival after third recurrence/progression. Ref = reference. R0 = no gross residual present at end of cytoreduction. R≤1 = gross residual disease ≤1 cm present at end of cytoreduction. R>1 cm = gross residual >1 cm present at end of cytoreduction. 95% CI = 95% confidence interval. p = p-value.
a
Characteristic at time of respective disease progression.